Table 2.

Change in parameters of systolic and diastolic function (compared to BL1) in supply ischemia protocol

	Baseline 1 (BL1)	Balloon occlusion 1 (BO1)		Baseline 2 (BL2)		Balloon occlusion 2 (BO2)
	%	Δ %	p value*	Δ %	p value*	Δ %	p value*
dP/dtmax
Control	100	−15.4 ± 13.6	0.012	−11.5 ± 10.0	<0.01	−25.7 ± 9.6	<0.001
GLP-1 only	100	−16.1 ± 10.2	<0.01	−0.3 ± 6.8	0.92	−12.8 ± 10.5	0.011
Glibenclamide only	100	−16.1 ± 14.4	0.011	−10.0 ± 4.7	<0.01	−21.7 ± 10.5	<0.01
GLP-1 glibenclamide	100	−13.5 ± 9.7	<0.01	−0.8 ± 9.0	0.82	−14.9 ± 9.2	<0.01
Ejection fraction
Control	100	−18.3 ± 14.1	0.01	−13.8 ± 15.5	0.03	−31.1 ± 16.0	<0.001
GLP-1 only	100	−17.9 ± 13.3	0.01	−8.4 ± 12.7	0.10	−11.7 ± 17.8	0.10
Glibenclamide only	100	−17.2 ± 13.4	0.01	−12.7 ± 19.6	0.14	−26.9 ± 14.2	<0.001
GLP-1 glibenclamide	100	−16.9 ± 13.8	0.01	−8.4 ± 4.8	<0.01	−13.1 ± 9.5	<0.01
Stroke volume
Control	100	−19.6 ± 18.1	0.03	−16.4 ± 16.3	0.02	−31.2 ± 16.6	<0.001
GLP-1 only	100	−19.8 ± 17.5	0.01	−5.8 ± 27.1	0.56	−12.6 ± 28.8	0.26
Glibenclamide only	100	−16.8 ± 17.8	0.08	−12.6 ± 18.2	0.12	−23.2 ± 22.1	0.04
GLP-1 glibenclamide	100	−14.8 ± 11.1	0.01	−0.2 ± 7.3	0.96	−5.6 ± 4.4	0.03
dP/dtmin
Control	100	−25.1 ± 14.7	<0.01	−10.9 ± 4.7	<0.001	−33.3 ± 8.6	<0.001
GLP-1 only	100	−21.3 ± 8.3	<0.001	+5.0 ± 11.6	0.26	−21.3 ± 8.7	0.04
Glibenclamide only	100	−26.4 ± 14.3	<0.001	−7.1 ± 12.5	0.17	−28.6 ± 13.1	<0.001
GLP-1 glibenclamide	100	−19.6 ± 6.1	<0.001	+2.9 ± 13.0	0.55	−14.3 ± 13.6	0.02
Tau
Control	100	+34.7 ± 16.9	<0.01	+12.7 ± 7.8	<0.01	+46.4 ± 15.4	<0.001
GLP-1 only	100	+27.3 ± 11.6	<0.001	+8.0 ± 18.6	0.26	+31.0 ± 36.7	0.05
Glibenclamide only	100	+30.5 ± 25.8	<0.01	+13.1 ± 19.9	0.14	+36.2 ± 26.3	<0.001
GLP-1 glibenclamide	100	+31.3 ± 27.2	<0.001	+5.5 ± 10.2	0.17	32.5 ± 13.2	<0.001

* p value compared to BL1 for each group